Enter assignee name

Forward Citations = 165

Loading Chart...

8 inventors (with patents filed for the assignee):

Jesse M Jaynes (8 out of 48 patents)

William R Belknap (3 out of 12 patents)

Gordon R Julian (3 out of 7 patents)

4. Joan Garbarino (2 out of 3 patents)

5. David M Rothstein (1 out of 8 patents)

6. Phillip M Friden (1 out of 13 patents)

7. Peter Spacciapoli (1 out of 6 patents)

8. Joan Garbabino (1 out of 1 patent)

9 patents: Sort by Forward Citations

1. 6559281 - Non-naturally occurring synthetic lytic peptides (2003-05-06),

2. 6528488 - Method for treating cystic fibrosis (2003-03-04),

3. 6514692 - Method for treatment of immunodeficiency virus infection (2003-02-04),

4. 6191110 - Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides (2001-02-20),

5. 6084156 - Plants producing lytic peptides (2000-07-04),

6. 6018102 - Ubiquitin-lytic peptide fusion gene constructs, protein products (2000-01-25),

7. 6001805 - Method of enhancing wound healing by stimulating fibroblast and (1999-12-14),

8. 5968904 - Modified arginine containing lytic peptides and method of making the (1999-10-19),

9. 5955573 - Ubiquitin-lytic peptide fusion gene constructs, protein products (1999-09-21),

Demegen, Inc. is a biotechnology company focused on developing novel therapies for infectious diseases. Using its proprietary platform, Demegen creates innovative treatments that target bacterial and viral pathogens. The company's mission is to address the growing problem of antibiotic resistance and improve patient outcomes. With a team of dedicated scientists and researchers, Demegen is committed to advancing the field of infectious disease therapeutics.

Profile summary based on public USPTO records.